Related Experiment Video
Updated: Jul 16, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Burkitt Lymphoma: Current Understanding, Unmet Needs, and Research Directions.
Adiba S Khan1, Cristina Lopez2, Suzanne D Turner1
1University of Cambridge, Cambridge, United Kingdom.
Blood Advances
|July 14, 2026
Summary
Burkitt lymphoma (BL) subtypes are now defined by genomics, not just clinical features. Advances offer new biomarkers and targeted therapies to improve survival, especially in resource-limited settings.
Area of Science:
- Hematology
- Genomics
- Epidemiology
Background:
- Burkitt lymphoma (BL) traditionally classified into endemic, sporadic, and immunodeficiency-associated types.
- Genomic studies reveal distinct EBV-positive and EBV-negative molecular subtypes.
- Significant survival disparities exist between high-income countries and sub-Saharan Africa (SSA).
Purpose of the Study:
- To review recent advances in Burkitt lymphoma epidemiology, molecular biology, diagnosis, and treatment.
- To highlight the impact of genomic insights on BL understanding and management.
- To identify opportunities for improving BL outcomes, particularly in resource-limited settings.
Main Methods:
- Review of current literature on Burkitt lymphoma.
- Analysis of genomic and epigenomic studies.
- Synthesis of epidemiological and clinical data.
Main Results:
- Genomic research has refined BL classification into molecular subtypes.
- Novel biomarkers for early detection and monitoring have been identified.
- Potential targeted therapies with reduced toxicity are emerging.
Conclusions:
- Genomic insights offer opportunities for scalable diagnostics and tailored therapies.
- Addressing survival disparities in BL requires improved access to care and targeted strategies.
- Further research is needed to understand therapeutic resistance and optimize treatment models.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...